Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Xiaoping Su"'
Autor:
Véronique Debien, Guillaume Davidson, Philippe Baltzinger, Jean-Emmanuel Kurtz, François Séverac, Alessio Imperiale, Patrick Pessaux, Pietro Addeo, Philippe Bachellier, Xiaoping Su, Irwin Davidson, Marie-Pierrette Chenard, Bernard Goichot, Gabriel G. Malouf
Publikováno v:
Cancers, Vol 13, Iss 11, p 2771 (2021)
Well-differentiated pancreatic neuroendocrine tumors (pNET) have an unpredictable natural history. The identification of both blood and tumor immune features associated with patients’ outcomes remains limited. Herein, we evaluated the best prognost
Externí odkaz:
https://doaj.org/article/fa06c8dc7cd444e48d171cf347ef2044
Autor:
Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel
Publikováno v:
Cancers, Vol 13, Iss 9, p 2170 (2021)
Purpose: To assess the efficacy and safety of bevacizumab plus erlotinib in patients with RMC. Methods: We retrospectively reviewed the records of patients with RMC treated with bevacizumab plus erlotinib at our institution. Results: Ten patients wer
Externí odkaz:
https://doaj.org/article/f0717f726cb04a5e94316de53f5115af
Autor:
François Severac, Philippe Baltzinger, Xiaoping Su, Guillaume Davidson, Jean-Emmanuel Kurtz, Véronique Debien, Patrick Pessaux, Irwin Davidson, Pietro Addeo, Gabriel G. Malouf, M. P. Chenard, Alessio Imperiale, Philippe Bachellier, Bernard Goichot
Publikováno v:
Cancers
Cancers, MDPI, 2021, 13 (11), pp.2771. ⟨10.3390/cancers13112771⟩
Cancers, Vol 13, Iss 2771, p 2771 (2021)
Volume 13
Issue 11
Cancers, 2021, 13 (11), pp.2771. ⟨10.3390/cancers13112771⟩
Cancers, MDPI, 2021, 13 (11), pp.2771. ⟨10.3390/cancers13112771⟩
Cancers, Vol 13, Iss 2771, p 2771 (2021)
Volume 13
Issue 11
Cancers, 2021, 13 (11), pp.2771. ⟨10.3390/cancers13112771⟩
Well-differentiated pancreatic neuroendocrine tumors (pNET) have an unpredictable natural history. The identification of both blood and tumor immune features associated with patients’ outcomes remains limited. Herein, we evaluated the best prognost
Autor:
Christopher G. Wood, Pavlos Msaouel, Vince D. Cataldo, Jose A. Karam, Giannicola Genovese, Andrew James Wiele, Kanishka Sircar, Eric Jonasch, Tharakeswara K. Bathala, Priya Rao, Amishi Yogesh Shah, Nizar M. Tannir, Devaki Shilpa Surasi, Xiaoping Su
Publikováno v:
Cancers
Cancers, Vol 13, Iss 2170, p 2170 (2021)
Volume 13
Issue 9
Cancers, Vol 13, Iss 2170, p 2170 (2021)
Volume 13
Issue 9
Simple Summary Renal medullary carcinoma (RMC) is a rare and highly aggressive renal cell carcinoma, with a median survival of 13 months. Platinum-based chemotherapy is the recommended standard of care for RMC, but no effective salvage regimens have